Rozeman, Elisa A <br/><br/>
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.  [electronic resource] 

 -  The Lancet. Oncology  07 2019 
 - 948-960 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(19)30151-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Ipilimumab--administration & dosage<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Nivolumab--administration & dosage<br/>Skin Neoplasms--drug therapy<br/>Young Adult